Healthcare Industry News: daytime sleepiness
News Release - June 30, 2008
SPO Medical Launching Enhanced PulseOx 7500(TM) Oximetry SystemHome Pre-Screening Sleep Apnea Device Now Supports Multiple Languages
NEW YORK, June 30 (HSMN NewsFeed) -- SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that it has released its PulseOx 7500(TM) supporting GUI (graphic user interface) and report generation in multiple languages including French, Italian, German and Spanish ("FIGS") along with English. The Company believes by supporting FIGS languages it will be able to address the growing interest in the PulseOx 7500(TM) across European markets and the Spanish speaking markets of the Americas.
Millions of people suffer from sleep apnea worldwide. Sleep apnea is a sleep disorder characterized by pauses in breathing during sleep. Each episode, called apneas, lasts long enough so that one or more breaths are missed, and occurs repeatedly throughout sleep disturbing a person's sleep pattern. Symptoms may be present for years, even decades without identification, during which time the sufferer may become conditioned to the daytime sleepiness and fatigue associated with significant levels of sleep disturbance. Such fatigue is known to be the cause of road accidents, industrial accidents and reduction in performance at the work place.
Typically, people with sleep disorder symptoms are referred by their primary care physician to third-party sleep clinics for overnight monitoring at the clinic facility, and depending on the diagnosis, are prescribed an appropriate medical remedy. The PulseOx 7500(TM) designed for maximum comfort and flexibility, enables doctors and other medical professionals to monitor patients from the convenience of the patient's home. Data is collected and stored overnight by wearing the PulseOx 7500(TM) wrist-watch configuration while the user sleeps; the next morning, the data is easily downloaded by the family care or general practitioner for analysis using supplied reporting software.
"We are delivering this new product feature as a direct result of increased demand from our European sales distributors. Those caring for sleep apnea sufferers recognize the value proposition of the PulseOx 7500(TM) and our cost-effective product is now available to a wider multi-language community as an effective pre-screening device for detecting sleep disorders in the comfort of a patient's home," commented Michael Braunold, President and CEO of SPO Medical. Mr. Braunold continued, "Introducing the additional languages once again demonstrates our commitment to extend our technological applications to meet the diverse needs of our worldwide customer base."
To date SPO Medical has introduced several other devices currently selling in close to 40 countries worldwide that use the Company's proprietary Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation (SpO2) and heart rate; they include the PulseOx 5500(TM) - a stand-alone homecare spot check monitor; Check Mate(TM) - a device for the sports and aviation markets that demand measuring SpO2 and heart rate during high-altitude activities; PulseOx 6000(TM), a professional stand-alone spot check monitor and the PulseOx 6100(TM) which is a professional hand-held monitor. Most recently the Company announced its entry in to the homecare baby monitoring market with its first product due in 2009.
About SPO Medical:
SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com and http://www.spobaby.com
Forward Looking Statements:
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, market acceptance of our new products, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.
Source: SPO Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.